Merck (6MK) Aktievy

Merck & Co, Inc. är ett globalt verksamt hälsovårdsföretag. Mer information

6MK fundamental analys
Snöflinga Score
Värdering	2/6
Framtida tillväxt	4/6
Tidigare resultat	1/6
Finansiell hälsa	3/6
Utdelningar	4/6

Belöningar

Handlar till 39% under vår uppskattning av dess verkliga värde

Intäkterna förväntas växa med 30.34% per år

Riskanalys

Aktier är mycket illikvida

Vinstmarginaler (4.8%) är lägre än förra året (25.8%)

Utdelning på 2.65% täcks inte väl av intäkterna

Stora engångsposter som påverkar finansiella resultat

+ 1 större risk

Last Earnings Call

Q2 2026 · 4 Aug 2026

Full Transcript

Merck & Co., Inc. reported Q2 2026 revenue of $16.6 billion, representing 5% growth (4% excluding foreign exchange), which beat the analyst consensus estimate of approximately $16.35–$16.41 billion. The company reported a non-GAAP loss of $0.13 per share, significantly better than the consensus estimate of a loss between $0.23 and $0.26 per share.

Management raised and narrowed its full-year 2026 revenue guidance to $66.3 billion–$67.3 billion. The full-year EPS outlook was adjusted to $2.66–$2.76, reflecting significant one-time charges related to the acquisitions of Terns Pharmaceuticals and Cidara. CEO Rob Davis emphasized strong execution in Oncology and Animal Health, along with key regulatory wins like the approval of LIPFENDRA. The company remains focused on a long-term commercial opportunity exceeding $70 billion from its pipeline.

Market Reaction

Merck shares rose approximately 1.4% in premarket trading on August 4, 2026. Analysts primarily cited the company’s strong "clean" earnings beat, robust Oncology sales (particularly KEYTRUDA), and the upward revision to full-year revenue guidance as the key drivers for the positive investor sentiment.

6MK Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW475,322 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

475,322 investors already sharing narratives

View all narratives

Merck & Co., Inc. Konkurrenter

Prishistorik och prestanda

Sammanfattning av aktiekursernas upp- och nedgångar samt förändringar för Merck
Historiska aktiekurser
Aktuell aktiekurs	US$104.82
52 veckors högsta	US$104.82
52 veckors lägsta	US$73.40
Beta	0.21
1 månads förändring	0%
3 månaders förändring	n/a
1 års förändring	53.47%
3 års förändring	n/a
5 års förändring	n/a
Förändring sedan börsintroduktionen	61.95%

Senaste nyheter och uppdateringar

Recent updates

Aktieägarnas avkastning

	6MK	BG Pharmaceuticals	BG Marknad
7D	0%	-1.6%	0.1%
1Y	53.5%	22.2%	11.7%

Avkastning vs industri: 6MK översteg BG Pharmaceuticals branschen som gav 22.2 % under det senaste året.

Avkastning vs Marknaden: 6MK översteg BG marknaden som gav 11.7 % under det senaste året.

Prisvolatilitet

Is 6MK's price volatile compared to industry and market?
6MK volatility
6MK Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	5.0%
Market Average Movement	4.8%
10% most volatile stocks in BG Market	8.1%
10% least volatile stocks in BG Market	3.1%

Stabil aktiekurs: 6MK s aktiekurs har varit volatil under de senaste 3 månaderna jämfört med marknaden för BG.

Volatilitet över tid: Otillräcklig data för att fastställa 6MK s volatilitetsförändring under det senaste året.

Om företaget

Grundad	Anställda	VD OCH KONCERNCHEF	Webbplats
1891	74,000	Rob Davis	www.merck.com

Merck & Co, Inc. är ett globalt verksamt hälsovårdsföretag. Verksamheten bedrivs genom två segment, Pharmaceutical och Animal Health. Företaget erbjuder humanläkemedel inom olika områden, bland annat onkologi, vacciner, akutvård på sjukhus, hjärt- och kärlsjukdomar, virologi, neurovetenskap och diabetes under varumärkena Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia och Janumet.

Merck & Co., Inc. Sammanfattning av grunderna

Hur förhåller sig Merck:s resultat och omsättning till dess börsvärde?
6MK grundläggande statistik
Börsvärde	€274.31b
Vinst(TTM)	€2.75b
Intäkter(TTM)	€57.60b

99.9x

P/E-förhållande

4.8x

P/S-förhållande

Är 6MK övervärderat?

Se Verkligt värde och värderingsanalys

Resultat & intäkter

Viktig lönsamhetsstatistik från den senaste resultatrapporten (TTM)
6MK resultaträkning (TTM)
Intäkter	US$66.57b
Kostnad för intäkter	US$16.01b
Bruttovinst	US$50.56b
Övriga kostnader	US$47.39b
Intäkter	US$3.17b

Senast redovisade vinst

Jun 30, 2026

Nästa vinstdatum

Oct 29, 2026

Vinst per aktie (EPS)	1.28
Bruttomarginal	75.95%
Nettovinstmarginal	4.77%
Skuld/egenkapitalförhållande	106.9%

Hur har 6MK utvecklats på lång sikt?

Se historisk utveckling och jämförelse

Utdelningar

2.6%

Aktuell utdelningsavkastning

259%

Utbetalningskvot

Företagsanalys och finansiella data Status

Uppgifter	Senast uppdaterad (UTC-tid)
Analys av företag	2026/08/07 01:36
Aktiekurs vid dagens slut	2026/06/11 00:00
Intäkter	2026/06/30
Årlig intjäning	2025/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

Paket	Uppgifter	Tidsram	Exempel US-källa
Företagets finansiella ställning	10 år	Resultaträkning Kassaflödesanalys Balansräkning	SEC Form 10-K SEC Form 10-Q
Analytikernas konsensusuppskattningar	+3 år	Prognos för finansiella poster Analytikernas prismål	Rapporter från analytiker Blue Matrix
Marknadspriser	30 år	Aktiekurser Utdelningar, splittar och åtgärder	ICE Marknadsdata SEC Form S-1
Ägarskap	10 år	Största aktieägare Insiderhandel	SEC Formulär 4 SEC Formulär 13D
Förvaltning	10 år	Ledningsgrupp Styrelse och verkställande direktörer	SEC Form 10-K SEC Form DEF 14A
Viktiga utvecklingstendenser	10 år	Företagsmeddelanden	SEC Formulär 8-K

^* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Merck & Co., Inc. bevakas av 49 analytiker. 23 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

Analytiker	Institution
David Toung	Argus Research Company
Charles Butler	Barclays
Emily Field	Barclays

Merck (6MK) Aktievy

Belöningar

Riskanalys

Market Reaction

Join community and earn perks

Merck & Co., Inc. Konkurrenter

Sopharma AD

Roche Holding

Tchaikapharma High Quality Medicines AD

Novartis

Prishistorik och prestanda

Senaste nyheter och uppdateringar

Merck Announces Health Canada Approval Of KEYTRUDA For Muscle Invasive Bladder Cancer Ineligible For Cisplatin Chemotherapy In Combination With Enfortumab Vedotin As Neoadjuvant And Adjuvant Treatment

Merck & Co., Inc. Updates Earnings Guidance for 2026

Merck & Co., Inc. Announces Quarterly Dividend for the Fourth Quarter of 2026, Payable on October 7, 2026

Merck Announces Initial Access Plans for Alimatravir, an Investigational Once-Monthly Oral HIV Pre-Exposure Prophylaxis in Phase 3 Development

Merck & Co., Inc. Receives U.S. FDA Approval For LIPFENDRA (Enlicitide) As The First Once-Daily Oral PCSK9 Inhibitor To Reduce LDL-C In Adults With Hypercholesterolemia

Merck Receives Fda Approval for Keytruda and Keytruda Qlex Each with Padcev as Treatment Before and After Surgery for Adults with Muscle-Invasive Bladder Cancer

Recent updates

Merck Announces Health Canada Approval Of KEYTRUDA For Muscle Invasive Bladder Cancer Ineligible For Cisplatin Chemotherapy In Combination With Enfortumab Vedotin As Neoadjuvant And Adjuvant Treatment

Merck & Co., Inc. Updates Earnings Guidance for 2026

Merck & Co., Inc. Announces Quarterly Dividend for the Fourth Quarter of 2026, Payable on October 7, 2026

Merck Announces Initial Access Plans for Alimatravir, an Investigational Once-Monthly Oral HIV Pre-Exposure Prophylaxis in Phase 3 Development

Merck & Co., Inc. Receives U.S. FDA Approval For LIPFENDRA (Enlicitide) As The First Once-Daily Oral PCSK9 Inhibitor To Reduce LDL-C In Adults With Hypercholesterolemia

Merck Receives Fda Approval for Keytruda and Keytruda Qlex Each with Padcev as Treatment Before and After Surgery for Adults with Muscle-Invasive Bladder Cancer

Merck Receives European Commission Approval For KEYTRUDA Plus Padcev as First PD-1 Inhibitor Plus Antibody-Drug Conjugate Regimen For Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer

Merck Reports Positive Topline Results From The Phase 3 ATLAS-UC Induction-Only Study Evaluating Tulisokibart In Patients With Moderately To Severely Active Ulcerative Colitis

Merck Receives U.S. FDA Approval for Expanded Indication of CAPVAXIVE Pneumococcal 21-Valent Conjugate Vaccine in Children and Adolescents Aged 2 Through 17 At Increased Risk for Pneumococcal Disease

Merck Receives Fda Approval for KEYTRUDA, KEYTRUDA QLEX, and WELIREG Combinations for Adjuvant Treatment of Clear Cell Renal Cell Carcinoma

Gilead Sciences, Inc. And Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, An Oral Once-Weekly HIV Treatment

Merck & Co., Inc. Grants Breakthrough Therapy Designation For Calderasib MK-1084 For First-Line Treatment Of Advanced Or Metastatic Non-Small Cell Lung Cancer With KRAS G12C-Mutation

Merck & Co., Inc. Declares Quarterly Dividend for the Third Quarter of 2026, Payable on July 8, 2026

Sieben Alexander, P.A. Secures $10.2 Million Verdict for Twin Cities Family Against Cosmetic Talc Manufacturers Vi-Jon and Four Co-Defendants—Gold Bond, Merck (Dr. Scholl's), Johnson & Johnson, and Perrigo Co. of Tennessee

Exelixis, Inc. Announces Clinical Development Collaboration with Merck for Phase 3 Stellar-316 Pivotal Trial for Patients with Colorectal Cancer

Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan Meets Primary Endpoints in Advanced or Recurrent Endometrial Cancer

Merck Highlights New Long-Term Data and Advancements Across Broad Oncology Portfolio and Pipeline Research At Asco 2026

Merck & Co., Inc. Updates Earnings Guidance for the Full Year 2026

Merck and Eisai Enter Announces FDA Approves Merck’S Once-Daily Idvynso (Doravirine/Islatravir)

Merck Announces FDA Grants Priority Review For Keytruda And Keytruda Qlex Each With Padcev For Cisplatin-Eligible Patients With Muscle-Invasive Bladder Cancer

Merck Announces European Commission Approval For Enflonsia (Clesrovimab) For Prevention Of Respiratory Syncytial Virus Lower Respiratory Tract Disease In Infants

Daiichi Sankyo And Merck Receive Priority Review For Ifinatamab Deruxtecan In Previously Treated Extensive-Stage Small Cell Lung Cancer

Merck & Co., Inc., Annual General Meeting, May 26, 2026

Merck Announces Initiation of Pivotal Phase 2B/3 Trial Evaluating Mk-8748 for Treatment of Neovascular Age-Related Macular Degeneration

Merck Announces Results for Enlicitide Decanoate, an Investigational Oral Pcsk9 Inhibitor

Merck & Co., Inc. Announces Positive Data from Phase 2 CADENCE Trial Provides Definitive Proof-of-Concept for WINREVAIR™ (sotatercept-csrk) in Adults With the Syndrome of Combined Post- and Precapillary Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction

Merck Reportedly Nears $6 Billion Deal to Buy Terns Pharma

Merck Presents New Data Reinforcing Long-Term Efficacy of Gardasil 9 and Gardasil At Eurogin International Multidisciplinary HPV Congress 2026

Merck Announces the Presentation of Results from the Pivotal Phase 3 Litespark-022 Trial Evaluating Keytruda

Merck & Co., Inc. Announces KEYTRUDA®? (Pembrolizumab) Plus Padcev®? (enfortumab Vedotin-Ejfv) Reduced Risk of Event-Free Survival Events by 47% and Risk of Death by 35% for Cisplatin-Ejfv

Merck & Co., Inc. Announces Late-Breaking Data from Three Phase 3 Trials Evaluating Doravirine/Islatravir (DOR/ISL) an Investigational, Once-Daily, Two-Drug Regimen for the Treatment of Adults Living with HIV-1 at CROI 2026

Merck & Co., Inc. Announces Executive Appointments and Organizational Changes in Human Health Business

Merck Announces Positive New Data for ENFLONSIA (Caresrovimab) for Infants and Children Under 2 Years of Age At Increased Risk for Severe Respiratory Syncytial Virus Disease over Two RSV Seasons

Merck announces Health Canada Approves KEYTRUDA SC™, a Subcutaneous Formulation of Pembrolizumab Across Multiple Cancer Indications

Merck Advances Treatment of Bladder and Kidney Cancers with New Data At 2026 ASCO GU Cancers Symposium

Merck Announces the U.S. Food and Drug Administration Approves KEYTRUDA (Pembrolizumab and Berahyaluronidase Alfa-Pmph) and KEYTRUDA QLEX

Chairman recently sold €4.7m worth of stock

Merck Announces Health Canada Approval of ENFLONSIA for the Prevention of RSV in Newborns and Infants

Full year 2025 earnings released: EPS: US$7.28 (vs US$6.76 in FY 2024)

Merck & Co., Inc. Provides Earnings Guidance for the Full Year 2026

Merck Declares Dividend on Common Stock for the Second-Quarter of 2026, Payable on April 7, 2026

MSD Reportedly Ends Takeover Talks with Revolution Medicines

Merck Reportedly in Talks to Buy Revolution in Up to $32 Billion Deal

Merck Initiates Phase 3 KANDLELIT-007 Trial Evaluating Calderasib in Combination with KEYTRUDA QLEX (Pembrolizumab and Berahyaluronidase Alfa-Pmph) in Certain Patients with Advanced NSCLC

Merck Reaches Agreement with U.S. Government to Expand Access to Medicines and Lower Costs for Americans

Merck Announces KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free Survival, Overall Survival and Pathologic Complete Response Rates for Cisplatin-Eligible Patients with MIBC When Given Before and After Surgery

Merck Receives Positive EU Chmp Opinion for Expanded Use of Winrevair™? (Sotatercept) in Adults with Pulmonary Arterial Hypertension (Pah, Who* Group 1 Pulmonary Hypertension)

Merck Showcases Data for Alzheimer's Disease Candidates MK-2214 and MK-1167 at CTAD 2025

Investor sentiment improves as stock rises 22%

FDA Approves Merck and KEYTRUDA (Pembrolizumab) and KEYTRUDA QLEX (Pembrolizumab and Berahyaluronidase Alfa-Pmph

Merck Announces Positive Topline Results from the Pivotal Phase 3 Trial Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravir (Dor/Isl) in Treatment-1 Infection

Merck Declares Dividend for the First Quarter of 2026, Payable on January 8, 2026

Merck Reportedly Close on A Deal to Buy Cidara

Merck's Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly ReducedDL-C in Adults with Heterozygous Familial Hypercholesterolemia in Phase 3 CORALreef HeFH Trial

Merck's Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly ReducedDL-C in Phase 3 CORALreef Lipids Trial

Merck & Co., Inc. Updates Earnings Guidance for the Year 2025

European Commission Approves KEYTRUDA® (Pembrolizumab) as Part of a Treatment Regimen for Adults with Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Expressing PD-L1 (CPS >1)

Merck Announces Positive Topline Results from the Phase 3 LITESPARK-022 Trial in Patients with Clear Cell Renal Cell Carcinoma

Merck & Co., Inc. Receives FDA Approval For Updated Indication Of WINREVAIR In Adults With PAH

Merck to Present New Data from Its Innovative Cardio-Pulmonary Pipeline and Portfolio At AHA Scientific Sessions 2025

Merck & Co., Inc. Announces the Presentation of Findings from Systematic Review of Studies on the Ep Epiiology and Antimicrobial Resistance of Pneumococcal Serotypes Covered by CapvaXIVE